Core Viewpoint - Zhaojin Gold has shown significant stock performance with a year-to-date increase of 207.30%, despite a recent decline of 2.09% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Zhaojin Gold reported revenue of 340 million yuan, representing a year-on-year growth of 119.51%, and a net profit attributable to shareholders of 82.16 million yuan, up 191.20% year-on-year [2] Stock Market Activity - As of November 26, Zhaojin Gold's stock price was 12.20 yuan per share, with a trading volume of 110 million yuan and a turnover rate of 0.98%, leading to a total market capitalization of 11.33 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on October 13 [1] Shareholder Information - As of November 20, the number of shareholders for Zhaojin Gold was 62,000, a decrease of 8.82% from the previous period, while the average number of circulating shares per person increased by 9.68% to 14,977 shares [2] - The top ten circulating shareholders include new entrants such as GF Strategy Preferred Mixed Fund and Hong Kong Central Clearing Limited, holding 12.73 million shares and 12.47 million shares respectively [3]

Core Viewpoint - Shandong Steel's stock has shown fluctuations with a recent increase of 2.04%, while the company has experienced a decline in revenue but a significant increase in net profit year-on-year [1][2]. Group 1: Stock Performance - As of November 26, Shandong Steel's stock price is 1.50 CNY per share, with a market capitalization of 16.048 billion CNY [1]. - The stock has increased by 3.45% year-to-date, but has seen declines of 3.23% over the last five trading days, 6.83% over the last 20 days, and 4.46% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Shandong Steel reported operating revenue of 54.828 billion CNY, a decrease of 14.77% year-on-year [2]. - The company achieved a net profit attributable to shareholders of 140 million CNY, reflecting a year-on-year increase of 109.64% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders is 199,000, a decrease of 3.98% from the previous period [2]. - The average number of circulating shares per shareholder is 53,767, an increase of 4.14% [2]. - The company has distributed a total of 3.474 billion CNY in dividends since its A-share listing, with 321 million CNY distributed in the last three years [3]. Group 4: Major Shareholders - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 98.304 million shares, an increase of 58.581 million shares from the previous period [3]. - Guotai CSI Steel ETF is the fifth-largest circulating shareholder, holding 53.728 million shares as a new shareholder [3].

Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

Core Viewpoint - Wantong Development's stock has shown a significant increase of 58.26% year-to-date, despite recent declines in the short term [1][2] Group 1: Stock Performance - As of November 26, Wantong Development's stock price rose by 2.25% to 11.79 CNY per share, with a trading volume of 243 million CNY and a turnover rate of 1.12%, resulting in a total market capitalization of 22.288 billion CNY [1] - The stock has experienced a slight decline of 0.17% over the last five trading days, a 3.76% drop over the last 20 days, and a 13.69% decrease over the last 60 days [1] - The company has appeared on the trading leaderboard 16 times this year, with the most recent instance on September 4, where it recorded a net buy of -280 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Wantong Development reported a revenue of 317 million CNY, reflecting a year-on-year decrease of 4.37%, while the net profit attributable to shareholders was -19.8 million CNY, showing a significant increase of 82.94% compared to the previous year [2] - The company has cumulatively distributed 1.421 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Group 3: Shareholder Structure - As of September 30, 2025, Wantong Development had 132,100 shareholders, an increase of 124.95% from the previous period, with an average of 14,309 shares held per shareholder, down 56.16% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 24.6642 million shares, an increase of 13.0461 million shares, while Shenwan Hongyuan Securities Limited has reduced its holdings by 5.7777 million shares to 19.7186 million shares [3]

Core Viewpoint - Nocera Biopharma has seen a significant increase in stock price and trading activity, indicating positive market sentiment and potential growth in the biopharmaceutical sector [1][2]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and R&D services [2]. Stock Performance - The stock price of Nocera Biopharma has increased by 110.02% year-to-date, with a recent 6.66% rise over the last five trading days and a 12.28% increase over the last 20 days, although it has seen a 10.76% decline over the past 60 days [2]. - As of November 26, the stock was trading at 25.79 CNY per share, with a market capitalization of 45.51 billion CNY [1]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion CNY, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was a loss of 64.41 million CNY, an improvement of 76.61% compared to the previous period [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 16,500, with no change in the average number of circulating shares per person [3]. - Notable changes in institutional holdings include a decrease in shares held by some funds and the entry of new shareholders, indicating a shift in investor interest [3].

Core Viewpoint - The stock of Visionox Technology Co., Ltd. has shown fluctuations, with a recent increase of 2.02% to 9.11 CNY per share, while the company has experienced a year-to-date decline of 11.38% [1] Financial Performance - For the period from January to September 2025, Visionox reported a revenue of 6.051 billion CNY, reflecting a year-on-year growth of 3.50%. However, the net profit attributable to shareholders was -1.623 billion CNY, which is an increase of 9.67% compared to the previous year [2] Shareholder Information - As of November 20, 2025, the number of shareholders for Visionox increased to 71,700, marking a rise of 14.69%. The average circulating shares per person decreased by 12.81% to 19,444 shares [2] Dividend Distribution - Since its A-share listing, Visionox has distributed a total of 53.2384 million CNY in dividends, with no dividends paid in the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Visionox, holding 11.0486 million shares, which is an increase of 2.8175 million shares from the previous period [3]

Core Viewpoint - Shentong Express has shown a significant stock price increase of 43.28% year-to-date, despite recent fluctuations in trading performance [1][2]. Company Overview - Shentong Express Co., Ltd. is located in Qingpu District, Shanghai, and was established on November 1, 2001. It was listed on September 8, 2010. The company primarily engages in domestic express delivery, general freight, cargo transportation agency, warehousing services, and unloading services [1]. - The main revenue composition of the company is 98.67% from express services and 1.33% from other businesses [1]. Financial Performance - For the period from January to September 2025, Shentong Express achieved an operating income of 38.57 billion yuan, representing a year-on-year growth of 15.17%. The net profit attributable to the parent company was 756 million yuan, with a year-on-year increase of 15.81% [2]. - Since its A-share listing, the company has distributed a total of 1.614 billion yuan in dividends, with 131 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shentong Express was 40,700, a decrease of 4.36% from the previous period. The average circulating shares per person increased by 2.81% to 36,082 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the sixth largest, holding 31.0712 million shares, a decrease of 12.1407 million shares compared to the previous period [3].

11月25日，海能达盘中上涨2.09%，截至14:18，报12.22元/股，成交8.25亿元，换手率5.36%，总市值 222.24亿元。 截至9月30日，海能达股东户数25.72万，较上期减少11.45%；人均流通股4987股，较上期增加12.94%。 2025年1月-9月，海能达实现营业收入37.46亿元，同比减少10.26%；归母净利润1.86亿元，同比减少 26.00%。 分红方面，海能达A股上市后累计派现3.09亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，海能达十大流通股东中，香港中央结算有限公司位居第三大流通 股东，持股1361.72万股，相比上期减少35.09万股。南方中证1000ETF（512100）位居第四大流通股 东，持股998.42万股，相比上期减少9.43万股。国泰中证全指通信设备ETF（515880）位居第五大流通 股东，持股658.96万股，相比上期增加374.02万股。华夏中证1000ETF（159845）位居第六大流通股 东，持股592.98万股，相比上期减少8100.00股。广发中证1000ETF（560010）位居第八大流通股东，持 股460 ...

Group 1 - The core viewpoint of the articles highlights the recent stock performance and financial metrics of Zhongyida, indicating a significant increase in stock price year-to-date but a recent decline over the past few trading days [1][2] - As of November 25, Zhongyida's stock price rose by 2.42% to 10.60 CNY per share, with a total market capitalization of 11.356 billion CNY [1] - The company has experienced a year-to-date stock price increase of 150.59%, but has seen declines of 9.56% over the last five trading days, 6.03% over the last 20 days, and 23.02% over the last 60 days [1] Group 2 - Zhongyida's main business involves the production and sales of fine chemical products, with revenue composition including 61.86% from pentaerythritol series products, 11.91% from edible alcohol, and 10.95% from trimethylolpropane series products [1] - For the period from January to September 2025, Zhongyida reported operating revenue of 762 million CNY, a year-on-year decrease of 6.07%, while net profit attributable to shareholders increased by 399.07% to 45.106 million CNY [2] - As of November 10, the number of shareholders in Zhongyida increased by 19.17% to 146,100, with an average of 0 circulating shares per shareholder [2]

Core Viewpoint - HNA Technology's stock price has shown significant volatility, with a year-to-date increase of 53.61% but a recent decline over the past few trading days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Group 1: Stock Performance - On November 25, HNA Technology's stock rose by 2.02%, reaching 4.04 CNY per share, with a trading volume of 174 million CNY and a turnover rate of 1.71%, resulting in a total market capitalization of 11.713 billion CNY [1]. - Year-to-date, HNA Technology's stock has increased by 53.61%, but it has experienced a decline of 12.17% over the last five trading days, 11.21% over the last 20 days, and 13.49% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on November 10, where it recorded a net buy of 73.4407 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, HNA Technology reported a revenue of 1.046 billion CNY, reflecting a year-on-year growth of 25.06%, while the net profit attributable to shareholders decreased by 13.29% to 96.8356 million CNY [2]. - The company's main business revenue composition includes 65.77% from merchandise trade, 33.27% from shipping, and 0.96% from other sources [1]. Group 3: Shareholder Information - As of September 30, 2025, HNA Technology had 76,500 shareholders, a decrease of 13.72% from the previous period, with an average of 0 circulating shares per shareholder [2]. - Among the top ten circulating shareholders, China Merchants Securities (Hong Kong) Limited is the fourth largest, holding 33.1104 million shares, an increase of 16.9263 million shares from the previous period [2].